H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $24.00 price target on Compass Therapeutics (NASDAQ: CMPX)The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Leerink on Compass Therapeutics (CMPX): 'there are multiple sources of long-term upside'April 27, 2026 10:20 AM Stifel on Compass Therapeutics (CMPX): 'Path Forward Complicated by FDA’s “Imply-No-Harm” Mandate'April 27, 2026 8:27 AM Compass Therapeutics stock plunges on trial data concerns, William Blair commentsApril 27, 2026 8:15 AM William Blair on Compass Therapeutics (CMPX) 75% Drop: 'This will raise questions on the approvability of this dataset'April 27, 2026 8:08 AM Form 8-K Compass Therapeutics, For: Apr 27April 27, 2026 7:30 AM Compass Therapeutics drug shows progression-free survival benefitApril 27, 2026 7:30 AM Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract CancerApril 27, 2026 7:30 AM Compass Therapeutics to host webcast on cancer drug trial dataApril 24, 2026 4:00 PM Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract CancerApril 24, 2026 4:00 PM